These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35489588)
21. Proteomic Characterization of Plasma Rich in Growth Factors and Undiluted Autologous Serum. Anitua E; Muruzabal F; Pino A; Prado R; Azkargorta M; Elortza F; Merayo-Lloves J Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830053 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Plasma Rich in Growth Factor in Patients with Congenital Aniridia and Dry Eye Disease. Lozano-Sanroma J; Barros A; Alcalde I; Alvarado-Villacorta R; Sánchez-Ávila RM; Queiruga-Piñeiro J; Cueto LF; Anitua E; Merayo-Lloves J Diseases; 2024 Apr; 12(4):. PubMed ID: 38667534 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the effects of platelet-rich or growth factor-rich plasma on intestinal anastomosis healing in pigs. Giusto G; Vercelli C; Iussich S; Tursi M; Perona G; Gandini M BMC Vet Res; 2017 Jun; 13(1):188. PubMed ID: 28629420 [TBL] [Abstract][Full Text] [Related]
24. The comparison effects of intra-articular injection of Platelet Rich Plasma (PRP), Plasma Rich in Growth Factor (PRGF), Hyaluronic Acid (HA), and ozone in knee osteoarthritis; a one year randomized clinical trial. Raeissadat SA; Ghazi Hosseini P; Bahrami MH; Salman Roghani R; Fathi M; Gharooee Ahangar A; Darvish M BMC Musculoskelet Disord; 2021 Feb; 22(1):134. PubMed ID: 33536010 [TBL] [Abstract][Full Text] [Related]
25. Initial experiences using plasma rich in growth factors to treat keratoneuralgia. Wang M; Yennam S; Pflugfelder S Front Med (Lausanne); 2022; 9():946828. PubMed ID: 36091697 [TBL] [Abstract][Full Text] [Related]
26. Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects. Suárez-Barrio C; Etxebarria J; Hernáez-Moya R; Del Val-Alonso M; Rodriguez-Astigarraga M; Urkaregi A; Freire V; Morales MC; Durán JA; Vicario M; Molina I; Herrero-Vanrell R; Andollo N Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987108 [TBL] [Abstract][Full Text] [Related]
28. Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases. Sánchez-Ávila RM; Uribe-Badillo E; Fernández-Vega González C; Muruzabal F; de la Sen-Corcuera B; Baamonde B; Quirós LM; Anitua E; Merayo-Lloves J Vision (Basel); 2021 Jul; 5(3):. PubMed ID: 34287367 [TBL] [Abstract][Full Text] [Related]
29. Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology. Anitua E; de la Fuente M; Alcalde I; Sanchez C; Merayo-Lloves J; Muruzabal F Transl Vis Sci Technol; 2020 Jun; 9(7):35. PubMed ID: 32832240 [TBL] [Abstract][Full Text] [Related]
30. Limbal stem cell transplantation: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2008; 8(7):1-58. PubMed ID: 23074512 [TBL] [Abstract][Full Text] [Related]
31. Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders. Sanchez-Avila RM; Merayo-Lloves J; Riestra AC; Berisa S; Lisa C; Sánchez JA; Muruzabal F; Orive G; Anitua E Medicine (Baltimore); 2018 Apr; 97(17):e0242. PubMed ID: 29702971 [TBL] [Abstract][Full Text] [Related]
32. In vitro effects of three blood derivatives on human corneal epithelial cells. Freire V; Andollo N; Etxebarria J; Durán JA; Morales MC Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5571-8. PubMed ID: 22786903 [TBL] [Abstract][Full Text] [Related]
33. Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease. Kawakita T; Uchino M; Fukagawa K; Yoshino K; Shimazaki S; Toda I; Tanaka M; Arai H; Sakatani K; Hata S; Okano T; Tsubota K Sci Rep; 2016 Feb; 6():20855. PubMed ID: 26865350 [TBL] [Abstract][Full Text] [Related]
34. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP; Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210 [TBL] [Abstract][Full Text] [Related]
35. Effects of three blood derived products on equine corneal cells, an in vitro study. Rushton JO; Kammergruber E; Tichy A; Egerbacher M; Nell B; Gabner S Equine Vet J; 2018 May; 50(3):356-362. PubMed ID: 29044680 [TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry Eye. Merayo-Lloves J; Sanchez-Avila RM; Riestra AC; Anitua E; Begoña L; Orive G; Fernandez-Vega L Ophthalmic Res; 2016 Jul; 56(2):68-73. PubMed ID: 27229893 [TBL] [Abstract][Full Text] [Related]
37. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops. Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245 [No Abstract] [Full Text] [Related]
38. Use of autologous plasma rich in growth factors fibrin membrane in the surgical management of ocular surface diseases. Sabater AL; Mousa HM; Quinones X; Valenzuela F; Sanchez Avila RM; Orive G; Anitua E; Merayo J; Perez VL Int Ophthalmol; 2021 Jul; 41(7):2347-2358. PubMed ID: 33745034 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Postorino EI; Rania L; Aragona E; Mannucci C; Alibrandi A; Calapai G; Puzzolo D; Aragona P Eur J Ophthalmol; 2018 Jan; 28(1):25-31. PubMed ID: 28777385 [TBL] [Abstract][Full Text] [Related]
40. Potential Effect of Plasma Rich in Growth Factors-Endoret in Stromal Wound Healing in Additive Surgery. Ibares-Frías L; Gallego-Muñoz P; Orive G; Anitua E; Cantalapiedra-Rodríguez R; Merayo-Lloves J; Martínez-García MC Ophthalmic Res; 2020; 63(2):203-212. PubMed ID: 31694028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]